{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:44:34Z","timestamp":1788864274939,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40262-026-01671-z","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:13:28Z","timestamp":1785377608000},"page":"1405-1414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Simulation-Based Predictions to Support the Development of a Pediatric Fixed-Dose Combination of Dolutegravir\/Emtricitabine\/Tenofovir Alafenamide Fumarate"],"prefix":"10.1007","volume":"65","author":[{"given":"Hylke","family":"Waalewijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3699-2993","authenticated-orcid":false,"given":"Lisanne A. H.","family":"Bevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda L.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret D.","family":"Louey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonoko","family":"Kawakatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Colbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin M.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"1671_CR1","unstructured":"UNAIDS. Global AIDS update. 2024."},{"issue":"9","key":"1671_CR2","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.1016\/S2352-3018(22)00101-1","volume":"9","author":"M Penazzato","year":"2022","unstructured":"Penazzato M, Townsend CL, Sam-Agudu NA, Ruel TD, Archary M, Bekker A, et al. Advancing the prevention and treatment of HIV in children: priorities for research and development. Lancet HIV. 2022;9(9):e658\u201366.","journal-title":"Lancet HIV."},{"key":"1671_CR3","unstructured":"EMA. Tivicay; summary of product characteristics 2022 [updated May 21, 2019]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002753\/WC500160680.pdf. Accessed 26 June 2026."},{"key":"1671_CR4","unstructured":"US FDA. Tivicay PD: clinical review(s). 2020."},{"key":"1671_CR5","unstructured":"EMA. Descovy: summary of product characteristics: 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004094\/WC500207650.pdf. Accessed 26 June 2026."},{"issue":"3","key":"1671_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/hiv.12702","volume":"20","author":"S Dakshina","year":"2019","unstructured":"Dakshina S, Olaru ID, Khan P, Raman L, McHugh G, Bwakura-Dangarembizi M, et al. Evaluation of weight-based prescription of antiretroviral therapy in children. HIV Med. 2019;20(3):248\u201353.","journal-title":"HIV Med"},{"key":"1671_CR7","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. Geneva: World Health Organization; 2021."},{"issue":"4","key":"1671_CR8","first-page":"526","volume":"29","author":"G Di Perri","year":"2021","unstructured":"Di Perri G. Tenofovir alafenamide (TAF) clinical pharmacology. Infez Med. 2021;29(4):526\u20139.","journal-title":"Infez Med"},{"issue":"12","key":"1671_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab542","volume":"8","author":"BR Wood","year":"2021","unstructured":"Wood BR, Huhn GD. Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter? Open Forum Infect Dis. 2021;8(12):ofab542.","journal-title":"Open Forum Infect Dis"},{"key":"1671_CR10","unstructured":"MusiimeV, Szubert AJ, Bwakura Dangarembizi M, Chabala C, Doerholt K, Dukakia N, et al., editors. Increasing second-line antiretroviral therapy options for children with HIV in Africa: week-96 efficacy and safety results of the CHAPAS-4 randomised trial. IAS; 23\u201326 July, 2023; Brisbane (QLD)."},{"issue":"7","key":"1671_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaf062","volume":"14","author":"E Natukunda","year":"2025","unstructured":"Natukunda E, Gaur AH, Deville JG, Kosalaraksa P, Strehlau R, Casta\u00f1o E, et al. Longitudinal evaluation of bone safety in children and adolescents with HIV-1 starting tenofovir alafenamide-containing antiretroviral therapy. J Pediatric Infect Dis Soc. 2025;14(7):piaf062.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"1671_CR12","unstructured":"US FDA. Tivicay: prescribing information. Updated June 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213983s000lbl.pdf. Accessed 26 June 2020."},{"key":"1671_CR13","unstructured":"US FDA. Descovy: prescribing information. [updated April 2017]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208215s001lbl.pdf. Accessed 26 June 2026."},{"key":"1671_CR14","unstructured":"US FDA. Clinical pharmacology and biopharmaceutics review. Dolutegravir (Tivicay). 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204790Orig1s000ClinPharmR.pdf. Accessed 26 June 2026."},{"issue":"10","key":"1671_CR15","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40262-023-01289-5","volume":"62","author":"H Chandasana","year":"2023","unstructured":"Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, et al. Population pharmacokinetic modeling of dolutegravir to optimize pediatric dosing in HIV-1-infected infants, children, and adolescents. Clin Pharmacokinet. 2023;62(10):1445\u201359.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1671_CR16","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1671_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40262-014-0140-7","volume":"53","author":"F Salem","year":"2014","unstructured":"Salem F, Johnson TN, Abduljalil K, Tucker GT, Rostami-Hodjegan A. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet. 2014;53(7):625\u201336.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1671_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/pharmaceutics11060259","volume":"11","author":"HM Back","year":"2019","unstructured":"Back HM, Lee JB, Han N, Goo S, Jung E, Kim J, et al. Application of size and maturation functions to population pharmacokinetic modeling of pediatric patients. Pharmaceutics. 2019;11(6):259.","journal-title":"Pharmaceutics"},{"key":"1671_CR19","unstructured":"WHO. WHO child growth standards: length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development 2006. https:\/\/www.who.int\/publications\/i\/item\/924154693X. Accessed 26 June 2026."},{"issue":"9875","key":"1671_CR20","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0140-6736(12)62198-9","volume":"381","author":"ARROW Trial Team","year":"2013","unstructured":"ARROW Trial Team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013;381(9875):1391\u2013403.","journal-title":"Lancet"},{"issue":"7","key":"1671_CR21","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1111\/bcp.14694","volume":"87","author":"RE Wasmann","year":"2021","unstructured":"Wasmann RE, Svensson EM, Walker AS, Clements MN, Denti P. Constructing a representative in-silico population for paediatric simulations: application to HIV-positive African children. Br J Clin Pharmacol. 2021;87(7):2847\u201354.","journal-title":"Br J Clin Pharmacol"},{"issue":"27","key":"1671_CR22","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","volume":"385","author":"A Turkova","year":"2021","unstructured":"Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. N Engl J Med. 2021;385(27):2531\u201343.","journal-title":"N Engl J Med"},{"issue":"1-2","key":"1671_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cca.2008.06.017","volume":"396","author":"H Pottel","year":"2008","unstructured":"Pottel H, Vrydags N, Mahieu B, Vandewynckele E, Croes K, Martens F. Establishing age\/sex related serum creatinine reference intervals from hospital laboratory data based on different statistical methods. Clin Chim Acta. 2008;396(1\u20132):49\u201355.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1671_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629\u201337.","journal-title":"J Am Soc Nephrol"},{"issue":"14","key":"1671_CR25","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1097\/QAD.0b013e32834a1dd9","volume":"25","author":"S Min","year":"2011","unstructured":"Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, et al. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25(14):1737\u201345.","journal-title":"AIDS"},{"issue":"2","key":"1671_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","volume":"12","author":"J van Lunzen","year":"2012","unstructured":"van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1671_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, et al. In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"1671_CR28","unstructured":"US FDA. Descovy: clinical pharmacology and biopharmaceutics review(s). 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208215Orig1_toc.cfm. Accessed 8 Sept 2021."},{"key":"1671_CR29","unstructured":"Custodio JM, Ting LS, Zack JZ, Majeed S, Yan M, Zhong J, et al., editors. Tenofovir alafenamide has wide efficacious range for treatment of HIV-1 infection: pharmacokinetic-pharmacodynamicrRelationship from a phase 3 study [abstract Sunday-407]. ASM Microbe; 16\u201320 June, 2016; Boston (MA)."},{"issue":"4","key":"1671_CR30","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/INF.0000000000000289","volume":"34","author":"X Saez-Llorens","year":"2015","unstructured":"Saez-Llorens X, Casta\u00f1o E, Rathore M, Church J, Deville J, Gaur A, et al. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression. Pediatr Infect Dis J. 2015;34(4):376\u201382.","journal-title":"Pediatr Infect Dis J"},{"key":"1671_CR31","unstructured":"US FDA. Emtriva: prescribing information. 2011. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm. Accessed 26 June 2026."},{"issue":"4","key":"1671_CR32","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/QAI.0000000000001699","volume":"78","author":"R Begley","year":"2018","unstructured":"Begley R, Das M, Zhong L, Ling J, Kearney BP, Custodio JM. Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals. J Acquir Immune Defic Syndr. 2018;78(4):465\u201372.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1671_CR33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40262-024-01365-4","volume":"63","author":"LAH Bevers","year":"2024","unstructured":"Bevers LAH, Kamphuis AEM, van der Wekken-Pas LCW, Leisegang R, Burger DM, Colbers A. Relative bioavailability of dolutegravir (DTG) and emtricitabine\/tenofovir alafenamide fumarate (F\/TAF) administered as paediatric tablet formulations in healthy volunteers. Clin Pharmacokinet. 2024;63(5):721\u20138.","journal-title":"Clin Pharmacokinet"},{"key":"1671_CR34","unstructured":"EMA. Viread; summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000419\/WC500051737.pdf. Accessed 26 June 2026."},{"issue":"4","key":"1671_CR35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/QAI.0000000000003810","volume":"101","author":"R Mpofu","year":"2025","unstructured":"Mpofu R, Chandiwana N, Sokhela S, Moorhouse M, Venter F, Anderson PL, et al. The effect of rifampicin on the plasma and intracellular pharmacokinetics of tenofovir alafenamide fumarate in participants with HIV-associated tuberculosis. J Acquir Immune Defic Syndr. 2025;101(4):424\u201331.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01671-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01671-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01671-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:23:10Z","timestamp":1788538990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01671-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1671"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01671-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was produced by the UNIVERSAL project, which is part of the EDCTP2 Programme supported by the European Union (grant number RIA2019PD-2882-UNIVERSAL). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of EDCTP.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yanan Zheng and Sonoko Kawakatsu are employees of Gilead Sciences, Inc., and hold stock in the company. Hylke Waalewijn, Lisanne A.H. Bevers, Linda L. Lewis, Margaret D. Louey, Carlo Giaquinto, Alessandra Nardone, David M. Burger, Rob ter Heine, Angela Colbers, and Elin M. Svensson is an Editorial Board member of Clinical Pharmacokinetics, but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The pharmacokinetic model for dolutegravir, adapted from ViiV Healthcare\u2019s publication, is included in the ESM. For the TAF\/TFV model, the situation is more complex. Through our collaboration, Gilead shared their TAF\/TFV model, which has been submitted to the US FDA as part of their pediatric TAF development program but it has not yet been published. Because of proprietary reasons, Gilead has provided permission to only share the model details provided in this article. We further adapted the Gilead TAF\/TFV model for our analyses. Data supporting the findings of this study are available from the corresponding author upon reasonable request, subject to applicable agreements and permissions.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code used for simulations is available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design. Simulations and data analysis were performed by HW and LB. All authors contributed to the drafting and revision of the manuscript and approved the final version.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}